Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Depreciation & Amortization (CF) (2016 - 2025)

Tg Therapeutics has reported Depreciation & Amortization (CF) over the past 10 years, most recently at $21000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $21000.0 for Q4 2025, up 133.33% from a year ago — trailing twelve months through Dec 2025 was $59000.0 (down 13.24% YoY), and the annual figure for FY2025 was $59000.0, down 13.24%.
  • Depreciation & Amortization (CF) for Q4 2025 was $21000.0 at Tg Therapeutics, up from $17000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for TGTX hit a ceiling of $80000.0 in Q4 2021 and a floor of $8000.0 in Q1 2025.
  • Median Depreciation & Amortization (CF) over the past 5 years was $48500.0 (2021), compared with a mean of $46150.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): tumbled 84.93% in 2024 and later surged 133.33% in 2025.
  • Tg Therapeutics' Depreciation & Amortization (CF) stood at $80000.0 in 2021, then dropped by 8.75% to $73000.0 in 2022, then plummeted by 47.95% to $38000.0 in 2023, then tumbled by 76.32% to $9000.0 in 2024, then surged by 133.33% to $21000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $21000.0 (Q4 2025), $17000.0 (Q3 2025), and $13000.0 (Q2 2025) per Business Quant data.